To view the fulltext, please log in
To view the pdf, please log in
Copyright / Drug Dosage
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
- Baethge C, Assall OP, Baldessarini RJ: Systematic review of blinding assessment in randomized controlled trials in schizophrenia and affective disorders 2000-2010. Psychother Psychosom 2013;82:152-160.
- Boutron I, Guittet L, Estellat C, Moher D, Hrobjartsson A, Ravaud P: Reporting methods of blinding in randomized trials assessing nonpharmacological treatments. PLoS Med 2007;4:e61.
- Manber R, Edinger JD, Gress JL, San Pedro-Salcedo MG, Kuo TF, Kalista T: Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia. Sleep 2008;31:489-495.
- Watanabe N, Furukawa TA, Shimodera S, Morokuma I, Katsuki F, Fujita H, Sasaki M, Kawamura C, Perlis ML: Brief behavioral therapy for refractory insomnia in residual depression: an assessor-blind, randomized controlled trial. J Clin Psychiatry 2011;72:1651-1658.
- Furukawa TA, Akechi T, Azuma H, Okuyama T, Higuchi T: Evidence-based guidelines for interpretation of the Hamilton Rating Scale for Depression (HAM-D). J Clin Psychopharmacol 2007;27:531-534.
- Morin CM, Vallieres A, Guay B, Ivers H, Savard J, Merette C, Bastien C, Baillargeon L: Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA 2009;301:2005-2015.
- Perlis RH, Ostacher M, Fava M, Nierenberg AA, Sachs GS, Rosenbaum JF: Assuring that double-blind is blind. Am J Psychiatry 2010;167:250-252.
- Basoglu M, Marks I, Livanou M, Swinson R: Double-blindness procedures, rater blindness, and ratings of outcome. Observations from a controlled trial. Arch Gen Psychiatry 1997;54:744-748.
- Boutron I, Estellat C, Ravaud P: A review of blinding in randomized controlled trials found results inconsistent and questionable. J Clin Epidemiol 2005;58:1220-1226.